NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
Phase 3ActiveDevelopment Stage
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
May 18, 2018 → Dec 31, 2026
About NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel is a phase 3 stage product being developed by ImmunityBio for Non Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03520686. Target conditions include Non Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non Small Cell Lung Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03520686 | Phase 3 | Active |
Competing Products
20 competing products in Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 40 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Selpercatinib | Eli Lilly | Pre-clinical | 26 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 40 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 33 |
| Pemetrexed | Eli Lilly | Pre-clinical | 26 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 35 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 29 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 22 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 32 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 37 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 27 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 35 |
| Cetuximab | Eli Lilly | Phase 1 | 29 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 40 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 35 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 36 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 39 |